David U’Prichard, PhD
Chairman Scientific Advisory Board
Dr. David C. U’Prichard is the Chairman of EDI’s Scientific Advisory Board (SAB). He is the former CSO, and current Advisory Board Chair and member of the Board of Managers of BioMotiv LLC (Cleveland). He also serves as a President of Druid Consulting LLC, consulting to the pharmaceutical and biotechnology industries from his base in Philadelphia, US, and as a Partner at Druid BioVentures LLP (Philadelphia). He currently sits on the advisory board of Militia Hill Ventures, an investment fund.
From 2015 until 2018, Dr. U’Prichard was a director of Arix Bioscience plc (LSE: ARIX), a public global healthcare and life science investment company based in London and New York. From 2005 until 2009, he was a Venture Partner at Red Abbey Venture Partners (Baltimore). During 2003–2006, he was a Venture Partner for Apax Partners Ltd. (London) and Care Capital LLC (Princeton). From 1999 to 2003 he was CEO of 3-
Dimensional Pharmaceuticals, Inc., Yardley PA. During that time he took 3DP public and secured large collaborations with Bristol-Myers Squibb and Johnson & Johnson. In March 2003, 3DP become a part of Johnson & Johnson Pharmaceutical R&D.
From 1997 to 1999, Dr. U'Prichard served as Chairman of Research and Development at SmithKline Beecham, managing 8000 R&D staff, and a portfolio of 200 projects. Prior to SmithKline Beecham, he worked for ICI/Zeneca from 1986 to 1997, as Executive Vice President and International Research Director from 1994 to 1997. While at Zeneca and SmithKline Beecham, Dr. U’Prichard oversaw the discovery and development of a number of successful drugs including Seroquel®, Accolate®, Avandia® and Iressa®.